Peps
RESEARCH FIELD GUIDE
From a promising mechanism to a useful finding
A practical way to read peptide research without turning an interesting experiment into a clinical promise.
Read the guide →Research field guides
Read beyond the headline. Original explainers connect the question, the experiment, and what remains unknown.
RESEARCH FIELD GUIDE
BPC-157 vs TB-500: compare the research, not the reputation
Tendon models, fragment identity, and a tiny eye-drop trial answer different questions. Here is how to keep them separate.
Read the guide →
RESEARCH FIELD GUIDE
Semaglutide, tirzepatide, retatrutide: why trial context changes the comparison
Understand direct comparisons, diabetes versus obesity populations, and the difference between glucose, weight, and cardiovascular outcomes.
Read the guide →RESEARCH FIELD GUIDE
MOTS-c and exercise: what happened in people, and what happened in mice
One paper can contain several kinds of evidence. An exercise-associated signal is different from a human treatment result.
Read the guide →
RESEARCH FIELD GUIDE
CJC-1295 and ipamorelin: a hormone signal is only part of the story
Why GH and IGF-I measurements, product identity, and a negative postoperative trial belong in the same research discussion.
Read the guide →
RESEARCH FIELD GUIDE
How to read a peptide certificate without confusing it with a guarantee
A worked example separates directory references, certificate IDs, batch numbers, reported results, and unanswered questions.
Read the guide →RESEARCH FIELD GUIDE
TB-500 vs thymosin beta-4: a fragment is not the whole protein
TB-500 and thymosin beta-4 are often used as if they were the same thing. They are not, and most of the human research involves the full protein, not the fragment sold as TB-500.
Read the guide →RESEARCH FIELD GUIDE
Melanotan I vs Melanotan II: one became a medicine, one did not
Melanotan I and Melanotan II were developed in the same lab to darken skin, but only Melanotan I (afamelanotide) became an approved medicine, for a rare light-sensitivity disease. Melanotan II has only tiny early studies and documented safety concerns.
Read the guide →RESEARCH FIELD GUIDE
Retatrutide phase 2 vs phase 3: what the new TRIUMPH trials add
Retatrutide's first large phase 3 results were published on September 29, 2026. They confirm large average weight loss seen in phase 2, in far more people over a longer time, and add results for knee osteoarthritis and sleep apnea.
Read the guide →RESEARCH FIELD GUIDE
Is BPC-157 FDA approved? What the FDA and the research actually say
No. BPC-157 is not approved by the FDA for any use, the FDA has flagged it as a compounding safety risk, and its healing evidence comes almost entirely from animal studies.
Read the guide →
RESEARCH FIELD GUIDE
Turn a podcast claim into a better research question
A short worksheet for following a discussion back to its evidence.
Read the guide →RESEARCH FIELD GUIDE
Before sharing an older episode, check the date and the product
How we separate historical podcast discussion from current regulatory source material.
Read the guide →